CD274 and non-small cell lung carcinoma: The randomized phase III study EMPOWER-Lung 1 was designed to evaluate first-line treatment with cemiplimab (anti-PD-1) monotherapy versus standard chemotherapy (platinum-based doublet) in patients with advanced NSCLC with PD-L1 expression ≥ 50% (n = 563).